Neuphoria Therapeutics (NASDAQ:NEUP) & Co-Diagnostics (NASDAQ:CODX) Financial Review

Neuphoria Therapeutics (NASDAQ:NEUP) and Co-Diagnostics (NASDAQ:CODX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

Valuation and Earnings

This table compares Neuphoria Therapeutics and Co-Diagnostics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$1.17 million	15.44	-$13.45 million	($6.22)	-0.54
Co-Diagnostics	$721,386.00	12.19	-$46.90 million	($10.32)	-0.12

Neuphoria Therapeutics has higher revenue and earnings than Co-Diagnostics. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Neuphoria Therapeutics and Co-Diagnostics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1	2	0	0	1.67
Co-Diagnostics	1	1	1	1	2.50

Neuphoria Therapeutics presently has a consensus target price of $7.00, indicating a potential upside of 109.58%. Co-Diagnostics has a consensus target price of $67.50, indicating a potential upside of 5,257.14%. Given Co-Diagnostics’ stronger consensus rating and higher possible upside, analysts clearly believe Co-Diagnostics is more favorable than Neuphoria Therapeutics.

Risk and Volatility

Neuphoria Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Comparatively, Co-Diagnostics has a beta of 2.9, indicating that its stock price is 190% more volatile than the S&P 500.

Profitability

This table compares Neuphoria Therapeutics and Co-Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-38.31%	-28.92%
Co-Diagnostics	-6,531.77%	-210.99%	-174.97%

Institutional and Insider Ownership

15.9% of Neuphoria Therapeutics shares are held by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are held by institutional investors. 1.5% of Neuphoria Therapeutics shares are held by insiders. Comparatively, 2.3% of Co-Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Neuphoria Therapeutics beats Co-Diagnostics on 8 of the 15 factors compared between the two stocks.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

About Co-Diagnostics

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.